{
    "pmcid": "10069166",
    "summary": "The paper titled \"Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus\" presents a computational approach to design antibodies that can bind with high affinity to multiple variants of the SARS-CoV-2 spike protein. The study leverages the RosettaAntibodyDesign (RAbD) protocol to achieve this goal. Here are the key insights related to the use of Rosetta in designing SARS-CoV-2 nanobody binders:\n\n### RosettaAntibodyDesign (RAbD) Overview:\n1. **Purpose and Approach**: RAbD is used to computationally redesign antibodies to improve their binding affinity and specificity for target antigens. In this study, the authors used RAbD to re-engineer the 80R antibody, which originally binds to SARS-CoV-1, to bind with high affinity to the SARS-CoV-2 spike protein.\n\n2. **Template Selection**: The 80R antibody was chosen as a template because it has a known crystal structure when bound to SARS-CoV-1, but it does not bind to SARS-CoV-2. This makes it an ideal candidate for demonstrating a specificity switch using computational design.\n\n3. **Design Workflow**: The workflow involves:\n   - Identifying antibody-antigen co-crystal structures with structural and sequence homology between SARS-CoV-1 and SARS-CoV-2.\n   - Using RAbD to design variants of the 80R antibody to bind SARS-CoV-2.\n   - Experimentally validating the designed antibodies for binding affinity.\n\n4. **Computational Process**: \n   - The RAbD protocol generated 4000 antibody designs using the 80R structure aligned to SARS-CoV-2.\n   - Different score functions and design options were employed to create a variety of designs.\n   - The designs were filtered and ranked based on predicted binding free energy and total energy scores.\n\n5. **Design Strategies**: \n   - Sequence design was allowed for specific regions (CDR loops) of the antibody.\n   - A designated CDR H3 design run was conducted, allowing mutations sampled from a database of CDR sequences with similar conformations.\n\n6. **Scoring and Selection**: \n   - Designs were ranked based on predicted binding energy and total energy.\n   - Manual inspection was used to identify favorable interactions at the antibody-antigen interface, such as hydrogen bonds and hydrophobic interactions.\n\n7. **Experimental Validation**: \n   - A subset of 30 antibody variants was expressed and purified for experimental testing.\n   - Binding affinities were measured using Biolayer Interferometry (BLI) and ELISA assays.\n\n8. **Results**: \n   - Of the 30 variants, 10 showed measurable binding to the SARS-CoV-2 spike protein, with KD values ranging from 0.468 nM to 114 nM.\n   - The variant 80R_5 demonstrated broad binding to multiple SARS-CoV-2 variants, including Omicron, Delta, Wuhan, and South African variants.\n\n### Insights and Implications:\n- **Rapid Design and Adaptability**: The RAbD-driven approach allows for rapid design and adaptation of antibodies to target new viral strains as they emerge, addressing the challenge of evolving SARS-CoV-2 variants.\n- **Cost and Speed**: Computational redesign offers advantages in terms of speed and cost compared to traditional methods of antibody discovery.\n- **Potential for Therapeutics**: The designed antibodies, particularly 80R_5, show potential as generalizable therapeutics that can bind to diverse SARS-CoV-2 variants.\n- **Limitations**: The approach focuses on increasing binding affinity, which may not directly translate to increased neutralization capability. Further experimental validation is necessary to confirm therapeutic efficacy.\n\nIn summary, the study demonstrates the utility of RosettaAntibodyDesign in the computational redesign of antibodies to target SARS-CoV-2, highlighting its potential to contribute to the rapid development of therapeutic antibodies against emerging viral pathogens.",
    "title": "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus"
}